Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play [Seeking Alpha]
Verastem, Inc. (VSTM)
Last verastem, inc. earnings: 10/29 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
verastem.com
Company Research
Source: Seeking Alpha
Company received FDA guidance to initiate registration-directed phase 2 trials for VS-7375 in KRAS G12D-mutated PDAC, NSCLC, and CRC. Upcoming 2026 milestones include pivotal data from RAMP 205 [PDAC], long-term RAMP 201 [LGSOC] results, and early VS-7375 data. Strong cash position [$234M pro forma] to fund operations into 1H 2027, minimizing dilution risk and supporting pipeline execution. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Piyaphorn Promnonsri/E+ via Getty Images Verastem Overview The last time I spoke about Verastem VSTM ) it was with a Seeking Alpha article entitled " Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC ." With respect to this article, I More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If yo
Show less
Read more
Impact Snapshot
Event Time:
VSTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VSTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VSTM alerts
High impacting Verastem, Inc. news events
Weekly update
A roundup of the hottest topics
VSTM
News
- Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026Business Wire
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers [Yahoo! Finance]Yahoo! Finance
- Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s CancersBusiness Wire
- Verastem (VSTM) was upgraded by BTIG Research to "strong-buy".MarketBeat
- Verastem (VSTM) had its "buy" rating reaffirmed by BTIG Research. They now have a $19.00 price target on the stock.MarketBeat
VSTM
Earnings
- 3/4/26 - Beat
VSTM
Sec Filings
- 3/23/26 - Form 4
- 3/4/26 - Form 8-K
- 3/4/26 - Form 10-K
- VSTM's page on the SEC website